Major investor and secret team behind outstanding return on biotech

Following a decade of dramatic ups and downs, Denmark’s most experienced biotech investor has made a remarkable change in strategy – backed by over one billion DKK from the Danish pensions group, ATP. It pays off.

Surrounded by a highly confidential network of international partners and specialists top-executive Florian Schönharting is now – through the consultancy company NB Capital – in the hunt for unique, stock market listed biotech- and pharmaceutical-groups on the larger, global stage in a fund that ATP has put “one billion+” into. The team behind NB Capital has also invested some millions in the fund, which was established in September of 2008. They have invested in approximately 20 companies so far, and most have been re-sold.

“As of the October 31st 2011 the raw return after management fees has on average been more than 35 % yearly, compared with a return of just a couple of per cent in the sector as a whole,” notes Florian Schönharting in the first interview that he has given about both the new strategy and the past decade, which could still become a winning decade in terms of return, or a disappointment for the investors who invested in the first two funds that focused mainly on smaller un-listed companies.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier